January 21, 2026 8:01am

There will be a reverberation, but for how long LPS (loss-per-share) earnings cycle is about to release beginning 2/5

Time to stay in-place after volatility surged

News, another Opinion: Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? https://finance.yahoo.com/news/fda-no-trial-stance-deramiocel-111135647.html I am NOT the only DISSENTER!  s Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump. https://finance.yahoo.com/news/capricor-therapeutics-capr-still-attractive-052444220.html

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Pre-open Signals: I am passing this a.m.; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t! 

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks. My thesis is important in trying to distinguish the temporary from real pricing digression or progress

RMi Closing Bell: A tug-of-war over words … https://www.regmedinvestors.com/articles/14274

RMi Research Note: Capricor Therapeutics (CAPR) Provides Regulatory Update on Deramiocel BLA… https://www.regmedinvestors.com/articles/14249

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt? … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The pre-open Dow futures are DOWN -0.27% or (-129 points), the S&P futures are DOWN -0.19% or (-13 points) and the Nasdaq futures are DOWN -0.34% or (-85 points)

  • U.S. stock futures slipping yet could exhibit a cautious recovery
  • European markets extended losses
  • Asia Pacific markets were mixed

Economic Data: Construction spending (delayed report) Oct. and Pending home sales

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Tuesday: The Dow closed DOWN -870.74 points or -1.76%, the S&P closed DOWN -143.15 points or -2.06% while the Nasdaq closed DOWN -561.065 points or -2.39%
  • Monday was a market holiday
  • Friday: The Dow closed DOWN -83.11 points or -0.17%, the S&P closed DOWN -4.46 points or -0.06% while the Nasdaq closed DOWN -14.634 points or -0.06%
  • Last week: The S&P 500 was down -0.4%, the Dow -0.3% and the Nasdaq was down -0.7%.
  • The previous week: The S&P 500 was up +1.6%, the Dow +2.3% and the Nasdaq was up +1.9%.

 

Q1/26 – Q1 – 2 holiday, 2 neutral, 4 negative and 3 positive closes  

Q4 – December,

  • 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • The peril facing the cell and gene therapy (C&GT) sector’s share pricing isn’t just applications of macro or even micro econs, sentiment or algorithms within electronic trading; it’s losing highly reliable, accurate and transparent data.

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

In 2026, investors should focus on whether cell and gene therapy sector equities can sustain momentum through clinical execution, regulatory milestones, commercialization progress, financings and potential strategic transactions; although Q4 and FY25 earnings cycle could slow upsides

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Investors are hoping for continued momentum, as they gauge the prospects for a Santa Claus rally.

  • after a surprise drop in inflation and lukewarm labor market data left betting on possible 2026 interest-rate cuts

 

January – 4th week:

  • 1/20 - Tuesday closed negative with 16 incliners, 22 decliners and 2 flats
  • 1/19 – Monday was a market holiday, MLK Jr day

January – 3nd week:

  • 1/16 – Friday closed negative with 11 incliners, 28 decliners and 1 flat
  • 1/15 - Thursday closed negative with 8 incliners, 30 decliners and 2 flats
  • 1/14 – Wednesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1/13 – Tuesday closed neutral with 19 incliners, 19 decliners and 2 flats
  • 1/12 – Monday closed neutral with 19 incliners, 19 decliners and 2 flats

January 2nd week

  • 1/9 - Friday closed negative with 10 incliners, 28 decliners and 2 flats
  • 1/8 – Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 1/7 – Wednesday closed positive with 33 incliners, 4 decliners and 2 flats
  • 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.